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Abstract We recently reported a facile method based on
the chelation of [18F]aluminum fluoride (Al18F) by NOTA
(1,4,7-triazacyclononane-1,4,7-triacetic acid). Here, we
present a further optimization of the 18F labeling of
NOTA-octreotide (IMP466). Octreotide was conjugated
with the NOTA chelate and was labeled with 18F in a
two-step, one-pot method. The labeling procedure was
optimized with regard to the labeling buffer, ionic strength,
peptide concentration, and temperature. Radiochemical
yield, specific activity, in vitro stability, and receptor
affinity were determined. Biodistribution of 18F-IMP466
was studied in AR42J tumor-bearing mice. In addition,
microPET/CT images were acquired. IMP466 was labeled
with Al18F in a single step with 97% yield in the presence
of 80% (v/v) acetonitrile or ethanol. The labeled product
was purified by HPLC to remove unlabeled peptide and
unbound Al18F. The radiolabeling, including purification,
was performed for 45 min. Specific activities of
48,000 GBq/mmol could be obtained. 18F-IMP466 showed
a high tumor uptake and excellent tumor-to-blood ratios at
2 h post-injection. In addition, the low bone uptake
indicated that the Al18F–NOTA complex was stable in
vivo. PET/CT scans revealed excellent tumor delineation
and specific accumulation in the tumor. Uptake in receptor-
negative organs was low. NOTA-octreotide could be
labeled with 18F in quantitative yields using a rapid two-
step, one-pot, method. The compound was stable in vivo
and showed rapid accretion in SSTR2-receptor-expressing
AR42J tumors in nude mice. This method can be used to
label other NOTA-conjugated compounds such as RGD
peptides, GRPR-binding peptides, and Affibody molecules
with 18F.
Keywords Octreotide . Radiofluorination . NOTA .
Peptide . PET. Aluminum fluoride
Introduction
Radiolabeled receptor-binding peptides have emerged as an
important class of radiopharmaceuticals that have changed
radionuclide imaging. Peptides have been labeled with 111In
and 99mTc for SPECT imaging and with positron emitters
such as 68Ga, 64Cu, 86Y, and 18F for PET imaging. 18F is the
most widely used radionuclide in PET and has excellent
characteristics for peptide-based imaging since the half-life
(110 min) matches the pharmacokinetics of most peptides.
In addition, the low positron energy of 635 keV results in
short ranges in tissue, which results in excellent preclinical
imaging resolution (<2 mm). Various methods to label
peptides with 18F have been investigated. Usually, a
nucleophilic substitution reaction is used to produce an
18F-labeled synthon, which is then reacted with a (function-
alized) peptide. One of the first generally applicable
methods—and still most widely used—is based on conju-
gation of the synthon, N-succinimidyl-4-[18F]fluoroben-
zoate, to a primary amino group of the peptide [1]. This
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method requires a time-consuming and laborious multistep
synthesis. Specific activities obtained with this method
ranged from 57,900 to 147,000 GBq/mmol [2]. Searching
for a faster method, Wester et al. developed an improved
18F-labeling method. This procedure is based on the
reaction of [18F]fluorobenzaldehyde with an aminooxy-
derivatized peptide, resulting in a stable oxime bond [3].
The specific activities of the radiolabeled peptides were not
mentioned. Others showed that [18F]fluorobenzaldehyde
could also be reacted with hydrazino nicotinamide-
conjugated peptides [4, 5]. The specific activity which
could be achieved with an 18F-labeled leukotriene B4
antagonist was 1,200 GBq/mmol [5]. To take advantage of
the widespread availability of [18F]FDG, two groups
explored [18F]FDG for labeling of aminooxy-derivatized
peptides [6, 7]. Although it was shown that these
functionalized peptides could be labeled with [18F]FDG,
these methods require the use of carrier-free [18F]FDG,
necessitating HPLC purification of [18F]FDG before con-
jugation with the peptide. Specific activities were not
reported. Additionally, methods based on the broadly used
Huisgen cycloaddition of alkynes and azides were explored
for the radiofluorination of peptides [8–12]. Specific
activities varied considerably from 4,800–12,300 GBq/
mmol [8] to 100,000–200,000 GBq/mmol [12]. In search
for a kit-based radiofluorination method, silicon-based
building blocks were used to fluorinate bombesin peptides.
To improve the stability of the 18F-labeled peptides, they
required to be functionalized with two tertiary butyl groups.
This resulted in a lipophilic 18F-peptide and loss of tumor
targeting [13, 14]. The maximal specific activity was
62,000 GBq/mmol. All of these methods require azeotropic
drying of 18F in the presence of a cryptand, such as
Kryptofix (K222).
We recently reported that NOTA-conjugated peptides
could be labeled directly with 18F using aluminum to bind
18F [15–17]. With this two-step one-pot fluorination
method, the peptide could be stably labeled with a 50%
radiochemical yield at a high-specific activity within
45 min. Here, we present an optimization of the aluminum
fluoride NOTA chelator labeling.
Materials and methods
Peptide synthesis
The octreotide peptide analog (IMP466), NOTA-D-Phe-
cyclo[Cys-Phe-D-Trp-Lys-Thr-Cys]-Throl (MH+ 1305),
was synthesized using standard Fmoc-based solid phase
peptide synthesis. After the peptide was cleaved from the
resin, the peptide was cyclicized by overnight incubation
with DMSO. The Throl resin and the protected amino acids
were purchased from CreoSalus Inc. (Louisville, KY). The
bis-t-butyl NOTA ligand was provided by Immunomedics,
Inc. All other chemicals were purchased from Sigma-
Aldrich (St. Louis, MO) or Fisher Scientific (Pittsburgh,
PA). All buffers used for radiolabeling were metal-free.
Radiolabeling
18F-labeling
A Chromafix PS-HCO3 cartridge (ABX, Radeberg,
Germany) with 4–6 GBq 18F (BV Cyclotron VU,
Amsterdam, The Netherlands) was washed with 3 mL of
metal-free water. 18F was eluted from the cartridge with
100 μL 0.9% NaCl. To the eluted Na18F, 2 mM AlCl3 in
0.1 M sodium acetate buffer, pH 4, was added (8.5 μl AlCl3
per GBq 18F). Then, 10–50 μL IMP466 (10 mg/mL) was
added in 0.5 M sodium acetate (pH 4.1) and also 6 mg/mL
gentisic acid. The reaction mixture was incubated at 100°C
for 15 min unless stated otherwise. The radiolabeled peptide
was purified on an RP-HPLC as described below. The 18F-
IMP466-containing fractions were collected and diluted
twofold with H2O and purified on an Oasis HLB cartridge
(1 cc, 30 mg, Waters, Milford, MA) to remove acetonitrile
and trifluoroacetic acid (TFA). In brief, the fraction was
applied on the cartridge and the cartridge was washed with
3 mL H2O. The radiolabeled peptide was then eluted with
2×200 μL 50% ethanol. Upon injection in mice, the peptide
was diluted with 0.9% NaCl.
Effect of buffer
The effect of the buffer on the labeling efficiency of
IMP466 with 18F− was investigated (n=3 for each buffer).
IMP466 was dissolved at 10 mg/mL (7.7 mM) in sodium
citrate buffer, sodium acetate buffer, 2-(N-morpholino)
ethanesulfonic acid (MES), or 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer. The mo-
larity of all buffers was 1 M and the pH was 4.1. To
153 nmol (200 μg) of IMP466, 100 μL Al18F (pH 4.1)
was added and incubated at 100°C for 15 min. Radio-
labeling yield and specific activity were determined with
RP-HPLC as described below.
Effect of hydrophilic organic solvent
The effect of the ionic strength on the labeling efficiency of
IMP466 with 18F was investigated (n=3 for each buffer).
To IMP466 [100 μg (77 nmol) in 25 μL in sodium acetate
buffer], 180 μL (unless stated otherwise) of acetonitrile,
ethanol, dimethylformamide (DMF), or tetrahydrofuran
(THF) was added [final concentration 80% (v/v)]. Finally,
20 μL Al18F (pH 4) was added and the mixture was
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incubated at 100°C for 15 min. Radiolabeling yield and
specific activity were determined with RP-HPLC as
described below.
Effect of temperature
The effect of the temperature on the labeling efficiency of
IMP466 with 18F was investigated (n=3 for each
temperature). To IMP466 [77 nmol (100 μg) in 25 μL in
sodium acetate buffer] 180 μL of acetonitrile and 20 μL
“Al18F” (pH 4) were added. The mixtures were incubated
at 40°C, 50°C, 60°C, or 100°C for 15 min. Radiolabeling
yield and specific activity were determined with RP-HPLC
as described below.
HPLC analysis
The radiolabeled preparations were analyzed by RP-HPLC
on an Agilent 1200 system (Agilent Technologies, Palo
Alto, CA, USA). Samples containing organic solvents were
diluted 50-fold before injection on HPLC. A C18 column
(Onyx monolithic, 4.6×100 mm, Phenomenex, Torrance,
CA, USA) was used at a flow rate of 2 mL/min with the
following buffer system: buffer A, 0.1% v/v TFA in water;
buffer B, 0.1% v/v TFA in acetonitrile; and gradient, 0–
5 min 97% buffer A, 5–35 min 80% buffer A to 75% buffer
A. The radioactivity of the eluate was monitored using an
in-line NaI radiodetector (Raytest GmbH, Straubenhardt,
Germany). Elution profiles were analyzed using Gina-star
software (version 2.18, Raytest GmbH, Straubenhardt,
Germany). Specific activity was determined by HPLC
using calibration curves based on the UV signal.
Stability
Ten microliters of the 18F-labeled IMP466 was incubated in
500 μL of freshly collected human serum and incubated for
4 h at 37°C. An equal volume of acetonitrile was added and
the mixture was vortexed followed by centrifugation at
1,000×g for 5 min to pellet the precipitated serum proteins.
The supernatant was analyzed on RP-HPLC as described
above.
The in vivo stability of 18F-IMP466 was examined by
injecting 18.5 MBq of 18F-IMP466 in a BALB/c nude
mouse. After 30 min, the mouse was euthanized and blood
and urine were collected and analyzed by HPLC.
Cell culture
The AR42J rat pancreatic tumor cell line was cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco Life
Technologies, Gaithersburg, MD, USA) supplemented with
4,500 mg/L D-glucose, 10% (v/v) fetal calf serum, 2 mmol/L
glutamine, 100 U/mL penicillin, and 100 μg/mL streptomy-
cin. Cells were cultured at 37°C in a humidified atmosphere
with 5% CO2.
IC50 determination
The apparent 50% inhibitory concentration (IC50) for
binding the somatostatin receptors on AR42J cells was
determined in a competitive binding assay using 19F-
IMP466 and 115In-DTPA-octreotide to compete for the
binding of 111In-DTPA-octreotide [16]. 19F-IMP466 was
formed by mixing an aluminum fluoride (AlF) solution
(0.02 M AlCl3 in 0.5 M NaAc, pH 4, with 0.1 M NaF in
0.5 M NaAc, pH 4) with IMP466 and heating at 100°C for
15 min. The reaction mixture was purified by RP-HPLC on
a C-18 column (30×150 mm, Sunfire, Waters, Milford,
MA), as described above.
115In-DTPA-octreotide was made by mixing indium
chloride (1×10−5 mol) with 10 μL DTPA-octreotide
(1 mg/mL) in 50 mM NaAc, pH 5.5, and incubated at
room temperature (RT) for 15 min. This sample was used
without further purification. 111In-DTPA-octreotide
(OctreoScan®) was radiolabeled according to the manufac-
turer’s protocol.
AR42J cells were grown to confluency in 12-well plates
and washed twice with binding buffer (DMEM with 0.5%
bovine serum albumin). After 10 min incubation at RT in
binding buffer, 19F-IMP466 or 115In-DTPA-octreotide was
added at a final concentration ranging from 0.1 to
1,000 nM, together with a trace amount (10,000 cpm) of
111In-DTPA-octreotide (radiochemical purity >95%). After
incubation at RT for 3 h, the cells were washed twice with
ice-cold PBS. Cells were scraped and cell-associated
radioactivity was determined. Under these conditions, some
internalization may occur. We therefore describe the results
of this competitive binding assay as “apparent IC50” values
rather than IC50. The apparent IC50 was defined as the
peptide concentration at which 50% of binding without
competitor was reached. Apparent IC50 values were
calculated using GraphPad Prism software (version 4.00
for Windows, GraphPad Software, San Diego, CA, USA).
Biodistribution studies
Male nude BALB/c mice (6–8 weeks old) were injected
subcutaneously with 0.2 mL AR42J cell suspension of 1×
107 cells/mL. When tumors were 5–8 mm in diameter,
370 kBq 18F-labeled IMP466 (0.2 nmol) was administered
intravenously (n=5). Separate groups of mice (n=5) were
co-injected with a 1,000-fold molar excess of unlabeled
IMP466. One group of three mice was injected with
unchelated (Al18F)2+. All mice were killed by CO2/O2
asphyxiation 2 h post-injection (p.i.). Tissues of interest
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were dissected, weighed, and counted in a gamma counter.
The percentage of the injected dose per gram tissue was
calculated. The animal experiments were approved by the
local animal welfare committee and performed according to
national regulations.
PET/CT imaging
Mice with s.c. AR42J tumors were injected intravenously
with 10 MBq 18F-IMP466 (0.7 nmol) per mouse. One and
2 h after the injection of peptide, mice were scanned on an
animal PET/CT scanner (Inveon®, Siemens Preclinical
Solutions, Knoxville, TN) with an intrinsic spatial resolution
of 1.5 mm [18]. The animals were placed in a supine position
in the scanner. PET emission scans were acquired over
15 min, followed by a CT scan for anatomical reference
(spatial resolution 113 μm, 80 kV, 500 μA). Scans were
reconstructed using Inveon Acquisition Workplace software
version 1.5 (Siemens Preclinical Solutions, Knoxville, TN),
using an ordered set expectation maximization-3D/maximum
a posteriori (OSEM3D/MAP) algorithm with the following
parameters: matrix 256×256×159, pixel size 0.43×0.43×
0.8 mm3, and a beta-value of 1.5.
Statistical analysis
All mean values are given ± standard deviation. Statistical
analysis was performed using a Welch’s corrected unpaired
Student’s t test or one-way analysis of variance using
GraphPad InStat software (version 3.06, GraphPad Soft-
ware). The level of significance was set at P<0.05.
Results
RP-HPLC analysis
As shown previously, HPLC analysis of the reaction
mixture (Fig. 1) demonstrated the presence of unbound
(Al18F)2+ (Rt 0.8 min) and two radioactive peptide peaks
with retention times of 17.4 and 19.8 min [16]. Recent date
revealed that these two peaks may be due to hindered
rotation of the complex with F-18 in an axial position [19].
In addition, a UV peak of IMP466 is present (Rt 21.4 min).
The radiolabeled 18F-IMP66 could be obtained carrier-free
after HPLC and HLB purification. This was confirmed by
HPLC analysis: both the unbound (Al18F)2+ and the
unlabeled IMP466 UV peaks disappeared (Fig. 1).
Effect of buffer
As reported previously, when the labeling procedure was
performed using sodium acetate, MES, or HEPES, radio-
labeling yields were 49±2%, 46±2%, and 48±3%, respec-
tively (n=3 for each buffer) [16]. In sodium citrate, no
radiolabeling was observed. Specific activities of the purified
peptides were in the same range for all buffers used. In
sodium acetate buffer, the specific activity was 32,000±
17,000 GBq/mmol, whereas in MES and HEPES buffers,
specific activities were 29,000±14,000 and 31,000±
23,000 GBq/mmol, respectively.
Effect of hydrophilic organic solvent
To investigate whether the labeling efficiency could be
improved by lowering the ionic strength, the labeling
reaction with (Al18F)2+ was performed in the presence of
increasing concentrations of acetonitrile: 25%, 50%, 67%,
or 80% (v/v) acetonitrile. Labeling efficiency at 25% was
40±5% and increased to 60±15% and 87±9% at 50% and
67%, respectively. Highest labeling efficiency was obtained
at 80% (v/v) acetonitrile, 97±2%.
In addition, the effect of other organic solvents was
investigated. Labeling efficiency in the presence of ethanol
and DMF was 97±2% and 97±3%, respectively. Radio-
labeling efficiency in THF was 92±7%. When the labeling
Fig. 1 RP-HPLC chromatograms of the IMP466 18F-labeling mix (a)
and the purified 18F-IMP466 (b). Red traces represent radioactivity
(left y-axis) and blue traces represent UV signal (right y-axis). In the
HPLC chromatogram of the crude mixture, unbound Al18F eluted with
the void volume (Rt=0.8 min). Two radioactive peaks correspond to
the stereoisomers of radiolabeled peptide (Rt=17.4 and Rt=19.8 min).
Finally, the unlabeled IMP466 was present in the UV channel (Rt=
21.4 min). After purification, only two radioactive peptide peaks are
observed, indicating the formation of two stereoisomers
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reaction was performed in the absence of organic solvent,
the labeling efficiency was 46±7%.
Effect of temperature
The effect of the incubation temperature was studied using
the optimal labeling condition described above, i.e., in the
presence of 80% (v/v) acetonitrile. Labeling efficiency
improved with increasing temperatures: at 40°C, the
labeling efficiency was 30±21%, and at 50°C, the yield
was 61±14%. At a temperature of 60°C, the labeling
efficiency was 83±19%.
IC50 determination
We previously demonstrated that the IC50 was not affected
by the radiofluorination [16]. Briefly, the apparent IC50 of
Al19F-labeled IMP466 was 3.6±0.6 nM. The apparent IC50
of the reference peptide, 115In-DTPA-octeotride (Octreo-
Scan®), was 6.3±0.9 nM. The affinity profiles are shown in
Fig. 2.
Stability
In line with previous results [16], 18F-labeled IMP466 did
not release (Al18F)2+ after incubation in human serum at
37°C for 4 h, indicating excellent stability of the Al18F-
NOTA-octreotide.
Biodistribution studies
The biodistribution of 18F-IMP466 in BALB/c nude mice
with s.c. AR42J tumors at 2 h p.i. is summarized in Fig. 3
(data adapted from [16]). Unchelated (Al18F)2+ was
included as a control. Tumor uptake of 18F-IMP466 was
28.3±5.7% ID/g at 2 h p.i. Tumor uptake in the presence of
an excess of unlabeled IMP466 was significantly decreased
(8.6±0.7% ID/g, P<0.002), indicating that tumor uptake was
receptor-mediated. Blood levels were low (0.10±0.07% ID/g,
2 h p.i.), which resulted in a tumor-to-blood ratio of 300±90.
Uptake in normal tissues, except in the kidneys, was low.
Receptor-mediated uptake was observed in SST2 receptor-
expressing tissues, such as adrenal glands, pancreas, and
stomach. Bone uptake of 18F-IMP466 was very low as
compared to uptake after injection of non-chelated (Al18F)2+
(0.33±0.07 vs. 36.9±5.0% ID/g at 2 h p.i., respectively; P<
0.001), indicating good in vivo stability of the 18F-IMP466.
Fused PET and CT scans are shown in Fig. 4. 18F-
IMP466 showed high uptake in the tumor and high
retention in the kidneys where the activity was localized
mainly in the renal cortex. In addition, some intestinal
uptake was observed. The PET/CT scans also demonstrated
that the (Al18F)2+ was stably chelated by the NOTA
chelator, since no bone uptake was observed.
Discussion
Radiolabeling of peptides with fluorine-18 generally
involves laborious and time-consuming procedures and
first requires the synthesis of an 18F-labeled synthon. In
our initial studies, we have shown that a NOTA-conjugated
pretargeting peptide (IMP449) could be labeled with Al18F
to yield a product with a good biodistribution profile [17].
These studies were performed with 18F− that was eluted
from a QMA cartridge with KHCO3 and required careful
neutralization with acetic acid in an effort to control the pH.
Subsequently, we found that the varying radiochemical
yields arising during the neutralization could be avoided if
the 18F− was eluted with 0.9% saline [15].
Fig. 2 Competitive binding assay (apparent IC50) of
19F-IMP466 and
115In-DTPA-octreotide determined on AR42J tumor cells. Values on
the y-axis represent binding expressed as a percentage of the binding
without competitor
Fig. 3 Biodistribution of 18F-IMP466 and unbound Al18F at 2 h p.i.
in AR42J tumor-bearing mice (n=5/group). Tumors weighed
0.07–0.36 g
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In the present study, we used a NOTA which was
covalently linked to the peptide, using one of the carboxylic
groups. Recent findings indicated that this chelator per-
formed equally well as the isothiocyanato-benzyl derivative
of NOTA [16, 17]. We found that the labeling of NOTA-
octreotide failed in the presence of sodium citrate buffer.
This might be due to the high affinity of citric acid for Al
(III), as described by Rajan et al. [20]. Recently, we
obtained considerable improvements in radiochemical
yields when the labeling was performed in the presence of
an organic hydrophilic solvent [19]. Herein we describe the
optimization of the 18F-labeling of NOTA-octreotide
(IMP466).
The labeling yield improved considerably when
performing the reaction at a lower ionic strength using
either acetonitrile, ethanol, or DMF. For subsequent experi-
ments, we used acetonitrile which could easily be evapo-
rated after the labeling reaction. Lowering the amount of
acetonitrile resulted in lower labeling yields. Obviously, for
future clinical studies, the use of ethanol is preferred over
acetonitrile.
The peptide concentration plays a crucial role in the
Al18F-NOTA-labeling reaction. A labeling yield of 52%
was obtained at a peptide concentration of 204 μM in the
presence of 67% acetontirile. In a previous study [16], a
peptide concentration of 1,815 μM was required to obtain a
50% labeling efficiency. This optimal concentration is
approximately tenfold lower as reported for other peptide
fluorination methods [1, 3, 5].
The radiolabeled peptide could be obtained carrier-free
after preparative HPLC separation on a monolithic C-18
column. Purification on a cartridge was not feasible due to
the small difference in organic solvent concentration
required to separate the labeled from the unlabeled peptide
on HPLC.
We demonstrated that the affinity of 18F-NOTA-octreotide
was at least as good as that of 111In-DTPA-octreotide and
was comparable with values reported in literature for DOTA-
octreotate and DOTA-TOC [21].
The biodistribution of the 18F-NOTA-octreotide was
studied in AR42J tumor-bearing mice. 18F-IMP466 showed
a high tumor uptake at 2 h p.i., with lower uptake in all
other organs. The in vivo studies also showed the excellent
stability of the Al18F–NOTA complex, since no significant
bone uptake could be measured, and the intact product was
isolated in the urine.
The current method can be performed in one pot, is fast
(45 min), yields carrier-free fluorinated peptide in nearly
quantitative yield, and does not affect the pharmacokinetics
of octreotide. In most 18F-labeling strategies for peptides
Fig. 4 Anterior 3D
volume-rendering projections
of fused PET and CT scans of
mice with a s.c. AR42J tumor
on the right flank injected with
18F-IMP466 (a) and with
18F-IMP466 in the presence of
an excess of unlabeled IMP466
(b). “T” indicates tumor, “K”
indicates kidneys, and “I”
indicate intestine. Scans were
recorded at 2 h p.i
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and proteins, a fluorinated synthon such as succinimidyl-
[18F]fluorobenzoate [1], 4-[18F]fluorobenzaldehyde [3], and
2-[18F]fluoropropionic acid 4-nitrophenyl ester [22] needs
to be synthesized first. In general, these fluorination
methods are based on a nucleophilic substitution which
requires laborious azeotropic drying of the [18F]fluoride/
kryptofix complex. Subsequently, these synthons are
reacted with the (functionalized) peptide, leading to longer
synthesis times and lower overall yields.
More recently, a method based on Si-F has been
published, in which the 18F is bound to a silicon-
containing building block in a single step [13, 14].
Although somewhat similar to our approach, the Si-18F
initially proved to be unstable, but could be stabilized by
the addition of tertiary butyl groups. This, however, leads to
a strong increase in lipohilicity (log P, 1.3±0.1).
Finally, “click” chemistry has been explored for the
radiofluorination of peptides [9–11]. Although the yield of
these click chemistry-based labeling procedures based on
the alkyne-azide cycloaddition is excellent (>80%), the
method starts with the fluorination of an azide or alkyne,
such as fluoro(ethyl)azide or a fluoroalkyne. This requires
azeotropic drying of the fluoride, resulting in a time-
consuming multistep procedure. Recently, the radiosyn-
thesis of a [18F]fluoroethyl triazole-labeled [Tyr3]octreotate
has been described using a copper-catalyzed azide-alkyne
cycloaddition reaction [8]. The [18F]fluoroethyl azide was
produced in 50% decay-corrected yields and the click
reaction proceeded in 5 min at room temperature in 50–
66% decay-corrected yields.
Compared to a 68Ga labeling, the Al18F method is easy
and versatile, mainly due to the fact that both methods are
based on a chelator-derivatized peptide. One of the
advantages of the AlF method is the longer half-life of
18F, allowing PET scanning at later timepoints after
injection of the tracer.
Conclusion
In conclusion, our new approach combines the ease of
chelator-based radiolabeling methods with the advantages of
18F (i.e., half-life, availability, and positron energy). The
Al18F-labeled NOTA-octreotide could be synthesized carrier-
free in quantitative yields in <45 min without the need to
synthesize an 18F synthon. Moreover, the fluorinated peptide
was stable in vitro and in vivo and has excellent tumor-
targeting properties. Therefore, this fluorination method is a
promising facile and versatile fluorination procedure.
Acknowledgments We thank Bianca Lemmers-de Weem and Kitty
Lemmens-Hermans for technical assistance. This work was funded in
part by NIH grant 5R44RR028018 from the National Center for
Research Resources, Bethesda, MD, to WJM.
Conflicts of interest WJM, CAD’S, and DMG are employed or
have financial interest in Immunomedics, Inc.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Lang L, Eckelman WC. One-step synthesis of 18F labeled [18F]-N-
succinimidyl 4-(fluoromethyl)benzoate for protein labeling. Appl
Radiat Isot. 1994;45:1155–63.
2. Lang L, Eckelman WC. Labeling proteins at high specific activity
using N-succinimidyl 4-[F-18](fluoromethyl) benzoate. Appl
Radiat Isot. 1997;48:169–73.
3. Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M,
Henriksen G, et al. Two-step methodology for high-yield routine
radiohalogenation of peptides: 18F-labeled RGD and octreotide
analogs. J Nucl Med. 2004;45:892–902.
4. Bruus-Jensen K, Poethko T, Schottelius M, Hauser A, Schwaiger
M, Wester HJ. Chemoselective hydrazone formation between
HYNIC-functionalized peptides and F-18-fluorinated aldehydes.
Nucl Med Biol. 2006;33:173–83.
5. Rennen HJ, Laverman P, van Eerd JE, Oyen WJ, Corstens FH,
Boerman OC. PET imaging of infection with a HYNIC-
conjugated LTB4 antagonist labeled with F-18 via hydrazone
formation. Nucl Med Biol. 2007;34:691–5.
6. Hultsch C, Schottelius M, Auernheimer J, Alke A, Wester HJ.
18F-Fluoroglucosylation of peptides, exemplified on cyclo
(RGDfK). Eur J Nucl Med Mol Imaging. 2009;36:1469–74.
7. Namavari M, Cheng Z, Zhang R, De A, Levi J, Hoerner JK, et al.
A novel method for direct site-specific radiolabeling of peptides
using [18F]FDG. Bioconjug Chem. 2009;20:432–6.
8. Iddon L, Leyton J, Indrevoll B, Glaser M, Robins EG, George
AJT, et al. Synthesis and in vitro evaluation of [F-18]fluoroethyl
triazole labelled [Tyr3]octreotate analogues using click chemistry.
Bioorg Med Chem Lett. 2011;21:3122–7.
9. GlaserM, Arstad E. "Click labeling" with 2-[18F]fluoroethylazide for
positron emission tomography. Bioconjug Chem. 2007;18:989–93.
10. Hausner SH, Marik J, Gagnon MK, Sutcliffe JL. In vivo positron
emission tomography (PET) imaging with an αvβ6 specific
peptide radiolabeled using 18F-“click” chemistry: evaluation and
comparison with the corresponding 4-[18F]fluorobenzoyl- and 2-
[18F]fluoropropionyl-peptides. J Med Chem. 2008;51:5901–4.
11. Marik J, Sutcliffe JL. Click for PET: rapid preparation of [F-18]
fluoropeptides using Cu-I catalyzed 1,3-dipolar cycloaddition.
Tetrahedron Lett. 2006;47:6681–4.
12. Li ZB, Wu Z, Chen K, Chin FT, Chen X. Click chemistry for 18F-
labeling of RGD peptides and microPET imaging of tumor integrin
alphavbeta3 expression. Bioconjug Chem. 2007;18:1987–94.
13. Hohne A, Mu L, Honer M, Schubiger PA, Ametamey SM,
Graham K, et al. Synthesis, 18F-labeling, and in vitro and in vivo
studies of bombesin peptides modified with silicon-based building
blocks. Bioconjug Chem. 2008;19:1871–9.
14. Mu L, Hohne A, Schubiger PA, Ametamey SM, Graham K, Cyr
JE, et al. Silicon-based building blocks for one-step 18F-radio-
labeling of peptides for PET imaging. Angew Chem Int Ed Engl.
2008;47:4922–5.
15. McBride WJ, D’Souza CA, Sharkey RM, Karacay H, Rossi EA,
Chang CH, et al. Improved 18F labeling of peptides with a fluoride-
aluminum-chelate complex. Bioconjug Chem. 2010;21:1331–40.
Tumor Biol. (2012) 33:427–434 433
16. Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen
WJG, et al. A novel facile method of labeling octreotide with (18)
F-fluorine. J Nucl Med. 2010;51:454–61.
17. McBride WJ, Sharkey RM, Karacay H, D’Souza CA, Rossi EA,
Laverman P, et al. A novel method of 18F radiolabeling for PET. J
Nucl Med. 2009;50:991–8.
18. Visser EP, Disselhorst JA, Brom M, Laverman P, Gotthardt M,
Oyen WJ, et al. Spatial resolution and sensitivity of the Inveon
small-animal PET scanner. J Nucl Med. 2009;50:139–47.
19. D’Souza C, McBride WJ, Sharkey RM, Todara LJ, Goldenberg
DM. High-yielding aqueous 18F-labeling of peptides via Al18F
chelation. Bioconjug Chem. 2011;22:1793–803.
20. Rajan KS, Mainer S, Rajan NL, Davis JM. Studies on the
chelation of aluminum for neurobiological application. J Inorg
Biochem. 1981;14:339–50.
21. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et
al. Affinity profiles for human somatostatin receptor subtypes SST1-
SST5 of somatostatin radiotracers selected for scintigraphic and
radiotherapeutic use. Eur J NuclMedMol Imaging. 2000;27:273–82.
22. Guhlke S, Wester HJ, Bruns C, Stocklin G. (2-[18F]fluoropro-
pionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for
quantitative somatostatin receptor imaging with PET: synthesis,
radiolabeling, in vitro validation and biodistribution in mice. Nucl
Med Biol. 1994;21:819–25.
434 Tumor Biol. (2012) 33:427–434
